Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations, expanding the addressable patient population by offering one solution for many mutations. Our mission: defeat cancer resistance and provide people living with cancer the opportunity to experience longer, healthier and more active lives. We are advancing two potent, brain-penetrant clinical-stage programs: BDTX-1535, a fourth-generation EGFR inhibitor targeting non-small cell lung cancer (NSCLC) and glioblastoma (GBM) and BDTX-4933, a RAF inhibitor targeting KRAS, NRAS and BRAF alterations in NSCLC and other solid tumors.

Biotechnology Value Fund

BVF Partners

City Hill Ventures

Wellington Management

Logos Capital

New Enterprise Associates

Invus

Nextech Invest

Roche Venture Fund

Versant Ventures

Perceptive Advisors

Black Diamond Therapeutics

Endpoints' recent coverage of a new survey on the state of the continuously evolving #NSCLC therapeutic landscape reflects progress for the field but still huge unmet need https://lnkd.in/e7AGnJqn. Fewer than one in five oncologists rated the current treatment options as excellent, and the majority are seeking additional treatment options for advanced forms of #cancer, as well as tools to assess biomarkers and other predictive methods that inform treatment efficacy. To learn more about BDTX's unique approach to expand the scope of NSCLC therapies and about its investigational MasterKey drug candidates, visit https://lnkd.in/eWvbfvKc

We expect an exciting year ahead as we continue advancing our clinical programs with the goal of enabling patients to live healthier, longer lives. We anticipate several important BDTX-1535 milestones in 2024, including Phase 2 results for the treatment of #NSCLC, as well as medical meeting presentations of Phase 1 data sets for the treatment of #GBM. We also expect BDTX-4933 Phase 1 results for the treatment of KRASm NSCLC.

Read more: https://lnkd.in/eMiiNsSg

#LungCancer #Glioblastoma

Today we announced topline results from our Phase 1 dose escalation trial in recurrent #GBM, where historical PFS ranges from 2-4 months. BDTX-1535 demonstrated promising clinical activity and more than 1/3 of patients remained on therapy greater than 4 months. These results in heavily pretreated patients are an important first step in understanding the potential of BDTX-1535 to benefit newly-diagnosed GBM patients. We anticipate results from a "window of opportunity" clinical trial of BDTX-1535 in second-line patients with high-grade glioma in 2Q 2024.

Read more: https://lnkd.in/eU7hFh8F

This weekend, Black Diamond will be in the Windy City, joining other pioneers in #oncology at the #IASLC North America Conference on Lung Cancer for robust knowledge exchange and immersion in the latest research as we further advance our pipeline of MasterKey inhibitors for #EGFR, #KRAS and #BRAF driven #NSCLC. 

To learn more about our pipeline, visit: https://lnkd.in/ek2kyjwV

#NACLC23

Lung cancer is the second most common form of cancer in both men and women in the US, according to the American Cancer Society, and November is #LungCancerAwareness Month. The more than 200,000 diagnoses each year inspire, encourage, and empower us every day to relentlessly pursue our mission of developing potentially life changing treatments for patients living with mutated forms of non small cell lung cancer: BDTX-1535 and BDTX-4933. #NSCLC #EGFR #KRAS

To read more about Lung Cancer Awareness Month, visit American Lung Association: https://lnkd.in/dnXYGtR

And to learn more about Black Diamond’s unique approach to targeting families of oncogenic mutations, click here: https://lnkd.in/em4gMAWM

	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-4.60M -	-8.93M 94.07%	-35.26M 294.78%	-67.25M 90.75%	-125.60M 86.75%	-91.17M 27.41%	-82.44M 9.57%
depreciation and amortization	24K -	44K 83.33%	47K 6.82%	52K 10.64%	205K 294.23%	508K 147.80%	437K 13.98%
deferred income tax	412K -			1.73M -	2.18M 26.32%		-597K -
stock based compensation	5K -	64K 1,180%	3.64M 5,592.19%	7.76M 113.15%	14.04M 80.77%	12.20M 13.11%	9.60M 21.26%
change in working capital	1.74M -	354K 79.70%	463K 30.79%	5.04M 988.98%	7.02M 39.23%	-9.90M 241.04%	3.69M 137.23%
accounts receivables
inventory
accounts payables	-59K -	264K 547.46%	1.45M 450.76%	1.07M 26.48%	1.57M 46.77%	-2.23M 242.13%	597K 126.77%
other working capital	1.80M -	90K 95.01%	-991K 1,201.11%	3.97M 500.91%	5.45M 37.20%	-7.67M 240.73%	3.09M 140.27%
other non cash items	66K -	15K 77.27%	6.43M 42,773.33%	524K 91.85%	2.01M 283.02%	3.28M 63.58%	2.60M 20.96%
net cash provided by operating activities	-2.35M -	-8.45M 259.59%	-24.67M 191.86%	-52.15M 111.34%	-100.15M 92.05%	-85.08M 15.04%	-66.72M 21.59%
investments in property plant and equipment	-77K -	-76K 1.30%	-21K 72.37%	-142K 576.19%	-2.71M 1,808.45%	-192K 92.92%	-33K 82.81%
acquisitions net				118K -	2.70M 2,188.14%	9K 99.67%	95K 955.56%
purchases of investments				-372.48M -	-49.51M 86.71%	-60.14M 21.48%	-61.89M 2.90%
sales maturities of investments				90.93M -	182.83M 101.07%	113.69M 37.82%	78.17M 31.24%
other investing activites				-118K -	-2.70M 2,188.14%
net cash used for investing activites	-77K -	-76K 1.30%	-21K 72.37%	-281.69M 1,341,285.71%	130.61M 146.37%	53.37M 59.14%	16.35M 69.37%
debt repayment	-50K -
common stock issued	100K -		129.50M -	213.84M 65.13%	729K 99.66%	177K 75.72%	71.93M 40,539.55%
common stock repurchased
dividends paid
other financing activites	9.92M -	52.31M 427.13%	-1.74M 103.33%	1.10M 163.11%
net cash used provided by financing activities	9.97M -	52.31M 424.48%	127.76M 144.22%	214.94M 68.25%	729K 99.66%	177K 75.72%	71.93M 40,539.55%
effect of forex changes on cash							345K -
net change in cash	7.55M -	43.78M 480.20%	103.06M 135.40%	-118.89M 215.36%	31.19M 126.24%	-31.54M 201.11%	21.91M 169.46%
cash at beginning of period	332K -	7.88M 2,272.89%	51.66M 555.75%	154.72M 199.50%	35.83M 76.84%	67.02M 87.07%	34.31M 48.80%
cash at end of period	7.88M -	51.66M 555.75%	154.72M 199.50%	35.83M 76.84%	67.02M 87.07%	35.48M 47.06%	56.22M 58.44%
operating cash flow	-2.35M -	-8.45M 259.59%	-24.67M 191.86%	-52.15M 111.34%	-100.15M 92.05%	-85.08M 15.04%	-66.72M 21.59%
capital expenditure	-77K -	-76K 1.30%	-21K 72.37%	-142K 576.19%	-2.71M 1,808.45%	-192K 92.92%	-33K 82.81%
free cash flow	-2.43M -	-8.53M 251.32%	-24.70M 189.51%	-52.29M 111.74%	-102.86M 96.71%	-85.27M 17.10%	-66.75M 21.72%

NASDAQ:BDTX

Black Diamond Therapeutics

Last Close

5.74

15/05 20:00

Market Cap

149.74M

Beta: 1.88

Volume Today

2.52M

Avg: 83.37K

PE Ratio

−2.55

PFCF: −2.76